Such drugs, generally identified by S1R binding, functional studies, and in silico and/or structural approaches, are viewed as potential treatments for neurodegenerative human conditions [33,34] such as Amyotrophic Lateral Sclerosis (ALS), retinal degeneration, Alzheimer’s, Parkinson’s Disease, and Huntington Disease. The gene discussed is TMBIM4; the disease is retinal degeneration.